Short Interest in Hypermarcas (OTCMKTS:HYPMY) Declines By 99.5%

Hypermarcas (OTCMKTS:HYPMY) was the recipient of a large decline in short interest in May. As of May 29th, there was short interest totaling 16 shares, a decline of 99.5% from the May 14th total of 3,352 shares. Approximately 0.0% of the company’s stock are short sold. Based on an average trading volume of 88,307 shares, the short-interest ratio is currently 0.0 days.

Hypermarcas Stock Up 2.9%

Shares of HYPMY traded up $0.12 during trading on Tuesday, reaching $4.08. The company’s stock had a trading volume of 7,845 shares, compared to its average volume of 34,566. The company has a fifty day moving average of $4.52 and a two-hundred day moving average of $4.48. Hypermarcas has a twelve month low of $3.71 and a twelve month high of $5.50. The company has a market cap of $2.87 billion, a price-to-earnings ratio of 8.49 and a beta of 0.70. The company has a quick ratio of 0.84, a current ratio of 1.27 and a debt-to-equity ratio of 0.61.

Hypermarcas (OTCMKTS:HYPMY) last announced its earnings results on Wednesday, April 29th. The company reported $0.10 earnings per share (EPS) for the quarter. The company had revenue of $383.13 million for the quarter. Hypermarcas had a return on equity of 14.08% and a net margin of 19.41%. On average, sell-side analysts predict that Hypermarcas will post 0.53 EPS for the current fiscal year.

Analyst Ratings Changes

Separately, Zacks Research raised Hypermarcas to a “hold” rating in a research report on Wednesday, April 29th. One analyst has rated the stock with a Strong Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Buy”.

About Hypermarcas

Hypermarcas SA is a Brazil-based consumer health and pharmaceutical company whose shares trade over the counter in the United States under the symbol HYPMY. Founded in the early 2000s and headquartered in Rio de Janeiro, the company operates as a holding group for a broad portfolio of branded products in the healthcare and personal care sectors.

Through its various subsidiaries, Hypermarcas develops, manufactures and markets prescription and over-the-counter medications, alongside personal care, baby care, home care and nutritional supplement products.